Pioneering the use of hyaluronic acid for rheumatic diseases

Rheumatic diseases affect joints, tendons, ligaments, bones, and muscles. These conditions affect 1.7 billion people globally and are the leading cause of disability.¹ There are over 150 forms of rheumatic disease, some of which are short-lived, but many are chronic.² These conditions often cause severe pain and limit mobility of the joint, impairing people’s ability to perform daily activities.

As part of our commitment to improving patients’ quality of life, we have been working in the rheumatology field for 25 years, delivering high quality pharmaceutical products with a high standard of safety. TRB Chemedica has pioneered the development of medical devices using sodium hyaluronate.

In 1998 we launched our first rheumatology product, Ostenil® — an intra-articular formulation for the treatment of osteoarthritis. This was part of our R&D focus to make an impactful difference for patients by bringing innovative treatments of controlled and natural origin. Since then, thanks to constant innovation, we have developed a range of formulations for different conditions and joints, bringing freedom of movement to more patients.

Yet, many people living with rheumatic disease are still without effective treatments. At TRB Chemedica, we are committed to keep innovating. We aim to bring disease-modifying treatments that slow disease progression, bring pain relief and improved mobility to a greater number of people to provide them with the quality of life they deserve.